NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Amgen
Accelerated Community Oncology Research Network
Christiana Care Health Services